Sanofi, GSK Covid Vaccine Triggers ‘Strong Immune Response’ As Firms Aim For Approval Later This Year A Phase 3 trial to test the vaccine’s efficacy is expected to start in a matter of weeks, with the vaccine showing potential to be a booster shot.